G01N 33/88
Involving prostaglandins or their receptors
Official title: involving prostaglandins {or their receptors}
G01N33/88 (Involving prostaglandins or their receptors) appears on 111 US grants and 151 published applications in this corpus.
Search patents in G01N- Granted patents
- 111
- Published applications
- 151
- Assignees
- 114
- Inventors
- 353
- Latest grant
- 8 Jul 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 1 | 0 |
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 5 | 0 |
| 1997 | 3 | 0 |
| 1998 | 4 | 0 |
| 1999 | 7 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 5 |
| 2002 | 4 | 12 |
| 2003 | 4 | 8 |
| 2004 | 1 | 11 |
| 2005 | 7 | 5 |
| 2006 | 4 | 6 |
| 2007 | 3 | 8 |
| 2008 | 1 | 4 |
| 2009 | 5 | 8 |
| 2010 | 5 | 11 |
| 2011 | 1 | 7 |
| 2012 | 3 | 3 |
| 2013 | 5 | 4 |
| 2014 | 4 | 4 |
| 2015 | 2 | 3 |
| 2016 | 3 | 3 |
| 2017 | 2 | 4 |
| 2018 | 3 | 11 |
| 2019 | 4 | 3 |
| 2020 | 0 | 7 |
| 2021 | 3 | 4 |
| 2022 | 3 | 5 |
| 2023 | 1 | 5 |
| 2024 | 1 | 3 |
| 2025 | 3 | 3 |
| 2026 | 0 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and systems for detecting prostaglandins by LC-MS/MS8 Jul 2025US 12,352,756 B2Laboratory Corporation of America Holdings
- MSC prediction algorithm15 Apr 2025US 12,276,655 B2Nextcell Pharma AB
- Control of cellular redox levels8 Apr 2025US 12,268,718 B2
- Methods and systems for detecting prostaglandins by LC-MS/MS2 Jul 2024US 12,025,619 B2Laboratory Corporation of America Holdings
- Antibody against human prostaglandin E2 receptor EP416 May 2023US 11,649,281 B2Nb Health Laboratory Co., Ltd.
- Postural orthostatic tachycardia syndrome and crth224 Sep 2026US 2026/0287597 A1Amerimmune LLC
- Bioassay method for hangeshashinto using pharmacological activity as indicator30 Jul 2026US 2026/0219260 A1Tsumura & Co.
- Leukotriene a4 hydrolase (lta4h) as (blood) biomarker for the diagnosis of polycystic ovarian syndrome5 Feb 2026US 2026/0036596 A1Roche Diagnostics Operations, Inc.
- Ratio between lta4h and metrnl in the assessment of polycystic ovarian syndrome5 Feb 2026US 2026/0036599 A1Roche Diagnostics Operations, Inc.
- Control of Cellular Redox Levels9 Oct 2025US 2025/0312396 A1
Most cited
By later US patents
- Nucleophilic polysubstituted aryl acridinium esters and uses thereof85US 5,241,070 ACiba Corning Diagnostics Corp. · 1993
- Prostaglandin E2 dual variable domain immunoglobulins and uses thereof85US 8,822,645 B2AbbVie Inc. · 2014
- Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity55US 5,543,297 AMerck Frosst Canada, Inc. · 1996
- Immunoassay employing an enzyme label42US 4,243,749 AHypolab S.A. · 1981
- Method for identifying and monitoring patients at risk for systemic inflammatory conditions and apparatus for use in this method35US 6,190,872 B12001